<DOC>
	<DOCNO>NCT01324570</DOCNO>
	<brief_summary>The purpose study characterize safety , PK , efficacy BTDS patient age 7 16 year .</brief_summary>
	<brief_title>Safety , Pharmacokinetics ( PK ) , Efficacy Buprenorphine Transdermal System ( BTDS ) Children</brief_title>
	<detailed_description>A study safety , PK , efficacy BTDS patient age 7 16 year , inclusive , require continuous opioid analgesia moderate severe pain .</detailed_description>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Inclusion Criteria include : Male female patient , 7 16 year age , inclusive , malignant and/or nonmalignant moderate severe pain requiring anticipate require continuous , aroundtheclock , opioid treatment least 2 week ( base investigator 's judgment ) ; Patients must write informed consent provide parent legal guardian assent provide patient , appropriate ; Patients incoming opioids must take ≤ 80 mg morphine equivalent age 12 16 year ≤ 40 mg morphine equivalent age 7 11 year prior initiation BTDS treatment ; Patients must able understand complete age appropriate scale rate pain intensity , ie , patient must cognitive developmental delay condition would preclude complete age appropriate pain scale ; Patients malignant and/or nonmalignant medical condition cause moderate severe pain require continuous , aroundtheclock opioid analgesic therapy cancer , sicklecell disease ( eg , result persistent body pain , persistent limb pain , avascular necrosis , persistent abdominal pain ) , persistent orthopedic pain ( eg , spinal injury , spinal disc herniation , persistent limb/stump pain , major trauma ) , juvenile rheumatoid arthritis ( pain control therapy treat underlying disease ) , cystic fibrosis result persistent chest pain ; Patients must parent/caregiver willing able compliant protocol , capable patient evaluation , able read understand questionnaire , willing able use diary , able read , understand , sign write informed consent . Exclusion Criteria include : Patients allergic buprenorphine history allergy opioids ( criterion include patient experienced common opioid side effect [ eg , nausea , constipation ] ) ; Patients allergies contraindication transdermal delivery system patch adhesive ; Patients dermatological disorder relevant patch application site would preclude proper placement and/or rotation BTDS patch ; Patients evidence impair renal function ; Patients hepatic impairment ; Patients history seizure ; Patients history sleep apnea within past year ; Patients unstable respiratory disease ; Patients structural heart disease pacemaker ; Patients clinically unstable cardiac disease ; Patients , opinion investigator , unsuitable participate study reason ; Patients receive anticipate receive investigational medication/therapy study drug treatment period . Other protocolspecific inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pain</keyword>
	<keyword>Opioid</keyword>
	<keyword>Analgesia</keyword>
	<keyword>Moderate severe pain</keyword>
</DOC>